Compare
NeuroPace Inc vs Beta Bionics, Inc. vs Kestra Medical Technologies, Ltd. vs Pulmonx Corp
| Latest fiscal year | NeuroPace Inc NPCE | Beta Bionics, Inc. BBNX | Kestra Medical Technologies, Ltd. KMTS | Pulmonx Corp LUNG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-04-30 | 2025-12-31 |
| Revenue | $99.99M | $100.25M | $95.13M | $90.50M |
| Revenue growth (YoY) | +25.1% | +53.9% | +59.0% | +8.0% |
| Gross margin | 77.2% | 55.4% | 51.4% | 74.2% |
| Operating margin | -16.3% | -71.5% | -141.6% | -59.3% |
| Net margin | -21.5% | -73.0% | -138.4% | -59.7% |
| Net income | -$21.46M | -$73.20M | -$131.61M | -$54.00M |
| EPS (Diluted) | -$0.66 | -$1.81 | -$2.43 | -$1.33 |
| Operating cash flow | -$11.01M | -$50.92M | -$81.70M | -$32.38M |
| Free cash flow | -$11.34M | -$56.22M | -$116.59M | -$32.83M |
| Cash & equivalents | $21.69M | $31.58M | $99.71M | $69.75M |
| Total assets | $105.56M | $328.74M | $358.46M | $129.29M |
| Total liabilities | $86.53M | $41.13M | $98.81M | $75.17M |
| Shareholders' equity | $19.03M | $287.61M | $259.66M | $54.12M |
| Return on year-end equity | -112.8% | -25.5% | -50.7% | -99.8% |
| Shares outstanding | 33.57M | 44.36M | 58.38M | 41.67M |
Revenue, most recent five fiscal years
| Fiscal year | NeuroPace Inc | Beta Bionics, Inc. | Kestra Medical Technologies, Ltd. | Pulmonx Corp |
|---|---|---|---|---|
| Latest | $99.99M Ended 2025-12-31 | $100.25M Ended 2025-12-31 | $95.13M Ended 2026-04-30 | $90.50M Ended 2025-12-31 |
| 1 year earlier | $79.91M Ended 2024-12-31 | $65.12M Ended 2024-12-31 | $59.81M Ended 2025-04-30 | $83.79M Ended 2024-12-31 |
| 2 years earlier | $65.42M Ended 2023-12-31 | $11.99M Ended 2023-12-31 | $27.81M Ended 2024-04-30 | $68.67M Ended 2023-12-31 |
| 3 years earlier | $45.52M Ended 2022-12-31 | n/a | n/a | $53.66M Ended 2022-12-31 |
| 4 years earlier | $45.18M Ended 2021-12-31 | n/a | n/a | $48.42M Ended 2021-12-31 |